Arthroplasty
Extended thromboprophylaxis with aspirin noninferior to dalteparin for THA patients
This report has been verified
by one or more authors of the
original publication.
Ann Intern Med. 2013 Jun 4;158(11):800-6. doi: 10.7326/0003-4819-158-11-201306040-00004
786 total hip arthroplasty (THA) patients were administered daily subcutaneous injections containing low-molecular-weight heparin (dalteparin) for 10 days, starting the next morning after surgery. Afterwards, patients were randomized to receive dalteparin injections in combination with placebo aspirin tablets or receive aspirin tablets combined with placebo dalteparin injections for 28 days, to compare the safety and efficacy of extended thromboprophylaxis. At 90 day follow-up, extended thromboprophylaxis with aspirin was noninferior to dalteparin in terms of venous thromboembolism and bleeding incidences. It should be noted that the study was terminated prematurely as the target sample size was not achieved due to difficulties with patient recruitment.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
